Michael Barbella, Managing Editor03.06.23
Stanford Medicine researchers have selected Cardiac Insight Inc.'s Cardea SOLO wearable ECG system for a medical study on atrial fibrillation (AF) in older women.
The study, "Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score," is measuring asymptomatic AF in older women, as the condition is associated with an increased stroke risk. The researchers want to determine the frequency of AF detected by serial, seven-day ECG patch screenings from patients identified as having an elevated risk of AF. The participants were mailed a Cardea SOLO ECG (electrocardiogram) patch monitor to be worn for seven days and returned for analysis.
Cardea SOLO is a lightweight, water-resistant ambulatory cardiac monitoring system. The wearable ECG sensor provides accurate results using Cardia Insight’s automated ECG data analysis and reporting software. Cardea SOLO’s ECG detection algorithms have a 99% PPV (Positive Predictive Value) for AF detection.
Another factor that makes Cardea SOLO suited for the study is its ergonomic design, according to the company. The Cardea SOLO disposable ECG biosensor has no cables and is comfortable and unobtrusive, encouraging patients to comply with prescribed wear times.
“We are delighted the research team elected to standardize on Cardea SOLO for their study,” Cardiac Insight CEO Min Kim said. “In this kind of research, it’s essential to have reliable, accurate results. We are proud of the sensitivity and accuracy of our wearable ECG monitoring system as we designed Cardea SOLO for in-office diagnostic procedures, so extracting patient data is easy and safe.”
In addition to AF, Cardea SOLO can detect more than 15 abnormal cardiac rhythms, including ventricular tachycardia, bradycardia, premature atrial contractions (PACs and other potentially serious arrhythmias).
Cardiac Insight is a U.S. digital healthcare innovation company developing medical-grade, body-worn sensor technology, and automated cardiac analysis solutions through its proprietary algorithms and software platforms. The company’s products include the Cardea SOLO wearable ECG Sensor and Software Analysis System, and the Cardea 20/20 ECG – the only resting 12-Lead ECG System designed for cardiac risk screening in young athletes at all levels of play.
The study, "Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score," is measuring asymptomatic AF in older women, as the condition is associated with an increased stroke risk. The researchers want to determine the frequency of AF detected by serial, seven-day ECG patch screenings from patients identified as having an elevated risk of AF. The participants were mailed a Cardea SOLO ECG (electrocardiogram) patch monitor to be worn for seven days and returned for analysis.
Cardea SOLO is a lightweight, water-resistant ambulatory cardiac monitoring system. The wearable ECG sensor provides accurate results using Cardia Insight’s automated ECG data analysis and reporting software. Cardea SOLO’s ECG detection algorithms have a 99% PPV (Positive Predictive Value) for AF detection.
Another factor that makes Cardea SOLO suited for the study is its ergonomic design, according to the company. The Cardea SOLO disposable ECG biosensor has no cables and is comfortable and unobtrusive, encouraging patients to comply with prescribed wear times.
“We are delighted the research team elected to standardize on Cardea SOLO for their study,” Cardiac Insight CEO Min Kim said. “In this kind of research, it’s essential to have reliable, accurate results. We are proud of the sensitivity and accuracy of our wearable ECG monitoring system as we designed Cardea SOLO for in-office diagnostic procedures, so extracting patient data is easy and safe.”
In addition to AF, Cardea SOLO can detect more than 15 abnormal cardiac rhythms, including ventricular tachycardia, bradycardia, premature atrial contractions (PACs and other potentially serious arrhythmias).
Cardiac Insight is a U.S. digital healthcare innovation company developing medical-grade, body-worn sensor technology, and automated cardiac analysis solutions through its proprietary algorithms and software platforms. The company’s products include the Cardea SOLO wearable ECG Sensor and Software Analysis System, and the Cardea 20/20 ECG – the only resting 12-Lead ECG System designed for cardiac risk screening in young athletes at all levels of play.